Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

已完结 10 由 necromme 发布于 2026/6/11 13:44:31

DOI:10.1016/s0140-6736(25)01778-7
作者：Laurie H Sehn, Kai Hübel, Stefano Luminari, Christian W Scholz, Antonio Salar, Shankara Paneesha, Bj?rn Engelbrekt Wahlin, Panayiotis Panayiotidis, Hui-Peng Lee, Ana Jiménez-Ubieto, Juan-Manuel Sanc
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundFollicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunot

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyHydroxyl Interfacial Engineering for Self-Assemble Monolayers Anchoring on NiO<sub>x</sub> Enables Efficient and Stable Perovskite Solar Cells.